4,6-Dimethyloctan-3,5-dione

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4,6-Dimethyloctan-3,5-dione
• 英文别名: 2,4-dimethyloctane-3,5-dione
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.25
• InChiKey: HMICEBPJFQKUJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PYRIDAZINE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3118200A1

  公开（公告）日：2017-01-18

  The present provides a pyridazine compound having an inhibiting effect on Stearoyl-CoA desaturase (SCD) (in particular, SCD1). The present provides a compound represented by formula (where each symbol is as defined as in the Specification) or a salt thereof

  本发明提供了一种对硬脂酰辅酶A去饱和酶（SCD）（特别是SCD1）具有抑制作用的吡啶啉化合物。本发明提供了一种由以下公式表示的化合物（其中每个符号如规范中定义）或其盐。
• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20210363130A1

  公开（公告）日：2021-11-25

  Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

  提供了一种可能具有优越的CDK12抑制作用并且预计可用作癌症等疾病的预防或治疗药物的化合物。具有以下化学式(I)所代表的化合物，其中每个符号如描述中所述，或其盐。
• HETEROCYCLIC COMPOUND AND USE THEREFOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150126487A1

  公开（公告）日：2015-05-07

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, a sleep disorder and the like. The present invention relates to a compound represented by the formula (I): wherein R 1 is an optionally substituted amino group or an optionally substituted cyclic amino group, R 2 and R 3 are each independently a hydrogen atom or a substituent, X is —CH═ or —N═, and ring A is an optionally substituted 5- to 10-membered ring, or a salt thereof.

  本发明提供了一种具有胆碱能肌动蛋白M1受体正变构调节剂活性的化合物，可用作预防或治疗阿尔茨海默病、精神分裂症、疼痛、睡眠障碍等药物。本发明涉及一种由式(I)表示的化合物：其中R1是可选取代的氨基或可选取代的环状氨基，R2和R3各自独立地是氢原子或取代基，X是—CH═或—N═，环A是可选取代的5-至10-成员环，或其盐。
• Fused heterocyclic compound
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US10577382B2

  公开（公告）日：2020-03-03

  Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein].

  本文提供了下式所代表的化合物或其盐： [其中各符号与本文定义相同]。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2921480B1

  公开（公告）日：2017-10-11